References
- Gaziano TA, Bitton A, Anand S, Weinstein MC. International Society of Hypertension. The global cost of nonoptimal blood pressure. J Hypertens 2009;27(7):1472–77. doi:10.1097/HJH.0b013e32832a9ba3.
- Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol 2021;18(11):785–802. doi:10.1038/s41569-021-00559-8.
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy339.
- NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet 2017;389(10064):37–55. doi:10.1016/S0140-6736(16)31919-5.
- Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol 2020;36(5): 596–624. doi:10.1016/j.cjca.2020.02.086.
- Patel KV, Li X, Kondamudi N, et al. Prevalence of apparent treatment-resistant hypertension in the United States according to the 2017 high blood pressure guideline. Mayo Clin Proc 2019;94(5):776–82. doi:10.1016/j.mayocp.2018.12.033.
- Mahfoud F, Himmel F, Ukena C, Schunkert H, Böhm M, Weil J. Treatment strategies for resistant arterial hypertension. Dtsch Arztebl Int 2011;108(43):725–31. doi:10.3238/arztebl.2011.0725.
- Modolo R, de Faria AP, Almeida A, Moreno H. Resistant or refractory hypertension: Are they different? Curr Hypertens Rep 2014;16(10):485. doi:10.1007/s11906-014-0485-1.
- Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory hypertension: A novel phenotype of antihypertensive treatment failure. Hypertension 2016;67(6):1085–92. doi:10.1161/HYPERTENSIONAHA.116.06587.
- Potthoff SA, Vonend O. Multidisciplinary approach in the treatment of resistant hypertension. Curr Hypertens Rep 2017;19(1):9. doi:10.1007/s11906-017-0698-1.
- Wei FF, Zhang ZY, Huang QF, Staessen JA. Diagnosis and management of resistant hypertension: State of the art. Nat Rev Nephrol 2018;14(7):428–41. doi:10.1038/s41581-018-0006-6.
- Böhm M, Linz D, Urban D, Mahfoud F, Ukena C. Renal sympathetic denervation: Applications in hypertension and beyond. Nat Rev Cardiol 2013;10(8):465–76. doi:10.1038/nrcardio.2013.89.
- Mahfoud F, Renkin J, Sievert H, et al. Alcohol-mediated renal denervation using the Peregrine System infusion catheter for treatment of hypertension. JACC Cardiovasc Interv 2020;13(4):471–84. doi:10.1016/j.jcin.2019.10.048.
- Mahfoud F, Edelman E, Bhatt N. Stereotactic radiotherapy for renal denervation: To beam, or not to beam? J Am Coll Cardiol 2019;74(13):1710–13. doi:10.1016/j.jacc.2019.07.054.
- Wei FF, Zhang ZY, Huang QF, Staessen JA. Diagnosis and management of resistant hypertension: State of the art. Nat Rev Nephrol 2018;14(7):428–41. doi:10.1038/s41581-018-0006-6.
- Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension 2011;57(5): 911–17. doi:10.1161/HYPERTENSIONAHA.110.163014.
- Symplicity HTN-2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet 2010;376(9756):1903–09. doi:10.1016/S0140-6736(10)62039-9.
- Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370(15):1393–1401. doi:10.1056/NEJMoa1402670.
- Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomised controlled trial. Lancet 2015;385(9981):1957–65. doi:10.1016/S0140-6736(14)61942-5.
- Rosa J, Widimský P, Toušek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: Six-month results from the Prague-15 study. Hypertension 2015;65(2):407–13. doi:10.1161/HYPERTENSIONAHA.114.04019.
- Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: A pilot study. Circulation 2011;123(18):1940–46. doi:10.1161/CIRCULATIONAHA.110.991869.
- Mahfoud F, Mancia G, Schmieder R, et al. Renal denervation in high-risk patients with hypertension. J Am Coll Cardiol 2020;75(23):2879–88. doi:10.1016/j.jacc.2020.04.036.
- Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): A multicentre, randomised, sham-controlled trial. Lancet 2020;395(10234):1444–51. doi:10.1016/S0140-6736(20)30554-7.
- Mahfoud F, Townsend RR, Kandzari DE, et al. Changes in plasma renin activity after renal artery sympathetic denervation. J Am Coll Cardiol 2021;77(23):2909–19. doi:10.1016/j.jacc.2021.04.044.
- Böhm M, Tsioufis K, Kandzari DE, et al. Effect of heart rate on the outcome of renal denervation in patients with uncontrolled hypertension. J Am Coll Cardiol 2021;78(10):1028–38. doi:10.1016/j.jacc.2021.06.044.
- Hawson J, Harmer JA, Cowan M, et al. Renal denervation for the management of refractory ventricular arrhythmias: A systematic review. JACC Clin Electrophysiol 2021;7(1):100–8. doi:10.1016/j.jacep.2020.07.019.
- Sharp TE III, Polhemus DJ, Li Z, et al. Renal denervation prevents heart failure progression via inhibition of the renin-angiotensin system. J Am Coll Cardiol 2018;72(21):2609–21. doi:10.1016/j.jacc.2018.08.2186.
- Mahfoud F, Böhm M, Schmieder R, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 2019;40(42):3474–82. doi:10.1093/eurheartj/ehz118.
- Li S, Phillips JK. Patient selection for renal denervation in hypertensive patients: What makes a good candidate? Vasc Health Risk Manag 2022;18:375–86. doi:10.2147/VHRM.S270182.
- Lohmeier TE, Hall JE. Device-based neuromodulation for resistant hypertension therapy. Circ Res 2019;124(7):1071–93. doi:10.1161/CIRCRESAHA.118.313221.
- Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: Results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011;58(7):765–73. doi:10.1016/j.jacc.2011.06.008.
- Yoruk A, Tankut SS, Gassler JP, Bisognano JD. Present and future of interventional treatment of resistant hypertension. Curr Hypertens Rep 2017;19(1):4. doi:10.1007/s11906-017-0702-9.
- Lobo MD, Sobotka PA, Pathak A. Interventional procedures and future drug therapy for hypertension. Eur Heart J 2017;38(15):1101–11. doi:10.1093/eurheartj/ehw303.
- Lobo MD, Sobotka PA, Stanton A, et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): A randomised controlled trial Lancet 2015;385(9978):1634–41. doi:10.1016/S0140-6736(14)62053-5.